RT Conference Proceedings
T1 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
A1 Powles, T. B.
A1 Chistyakov, V.
A1 Beliakouski, V.
A1 Semenov, A.
A1 Everaert, E.
A1 Baranau, Y.
A1 Moreno, V.
A1 Valderrama, B. Perez
A1 Vano, Y.
A1 Del Conte, G.
A1 Loriot, Y.
A1 Kang, T. W.
A1 Tammaro, M.
A1 O'Hagan, A.
A1 Hosseini, M.
A1 Triantos, S.
A1 Chhabra, H.
A1 Santiago-Walker, A.
A1 Siefker-Radtke, A. O.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/27230
UL https://hdl.handle.net/10668/27230
LA en
DS RISalud
RD Apr 6, 2025